Shijun Li1, Xiaoying Li2. 1. Department of Geriatric Cardiology, Chinese PLA General Hospital, No. 28, Fuxing Road, Beijing, 100853, People's Republic of China. lishijun817@126.com. 2. Department of Geriatric Cardiology, Chinese PLA General Hospital, No. 28, Fuxing Road, Beijing, 100853, People's Republic of China.
Abstract
INTRODUCTION: Prognostic significance of heart rate (HR) in heart failure with preserved ejection fraction (HFpEF) remains poorly understood. AIM: To evaluate the association of HR and beta-blocker use with all-cause mortality and the optimal HR range in patients with HFpEF and sinus rhythm (SR). METHODS: During a follow-up of 2.7 years (IQR 1.2-4.1 years), the 330 patients with median age 73 (IQR 64-79) years, 52.1% men, were included. HFpEF was defined as patients with EF ≥ 50%. The outcome measure was all-cause mortality. RESULTS: In total, 96 (29.1%) of patients with HFpEF and SR died. A linear tendency between HR and mortality was observed in SR. Compared to the reference strata HR ≤ 60 bpm, HR increment was associated with progressively increased risk in mortality (Chi-square = 13.90, Log rank P = 0.001) by Kaplan-Meier analyses. Univariate Cox regression showed that in SR, compared with that in HR 61-80 bpm, the unadjusted hazard ratios for mortality were 0.41 (95% CI 0.23-0.74, P = 0.003) in HR ≤ 60 bpm, 1.38 (95% CI 0.85-2.24, P = 0.189) in HR > 80 bpm. Multivariate Cox regression showed that compared with that in HR 61-80 bpm, the adjusted hazard ratios for mortality were 0.37 (95% CI 0.19-0.75, P = 0.005) in HR ≤ 60 bpm, 0.96 (95% CI 0.52-1.74, P = 0.899) in HR > 80 bpm. Univariate Cox regression showed that the unadjusted hazard ratios for mortality were 0.52 (95% CI 0.33-0.84, P = 0.003) in patients with beta-blocker as compared patients without beta-blocker. Multivariate Cox regression showed that the adjusted hazard ratios for mortality were 0.48 (95% CI 0.26-0.87, P = 0.016) in patients with beta-blocker as compared patients without beta-blocker. CONCLUSIONS: HR is independently associated with increased all-cause mortality in SR and a lower HR (≤ 60 bpm) is favorable for better outcome in HFpEF patients with SR. Beta-blocker use is associated with reduced mortality and a lower HR is associated with reduced mortality in HFpEF patients with SR.
INTRODUCTION: Prognostic significance of heart rate (HR) in heart failure with preserved ejection fraction (HFpEF) remains poorly understood. AIM: To evaluate the association of HR and beta-blocker use with all-cause mortality and the optimal HR range in patients with HFpEF and sinus rhythm (SR). METHODS: During a follow-up of 2.7 years (IQR 1.2-4.1 years), the 330 patients with median age 73 (IQR 64-79) years, 52.1% men, were included. HFpEF was defined as patients with EF ≥ 50%. The outcome measure was all-cause mortality. RESULTS: In total, 96 (29.1%) of patients with HFpEF and SR died. A linear tendency between HR and mortality was observed in SR. Compared to the reference strata HR ≤ 60 bpm, HR increment was associated with progressively increased risk in mortality (Chi-square = 13.90, Log rank P = 0.001) by Kaplan-Meier analyses. Univariate Cox regression showed that in SR, compared with that in HR 61-80 bpm, the unadjusted hazard ratios for mortality were 0.41 (95% CI 0.23-0.74, P = 0.003) in HR ≤ 60 bpm, 1.38 (95% CI 0.85-2.24, P = 0.189) in HR > 80 bpm. Multivariate Cox regression showed that compared with that in HR 61-80 bpm, the adjusted hazard ratios for mortality were 0.37 (95% CI 0.19-0.75, P = 0.005) in HR ≤ 60 bpm, 0.96 (95% CI 0.52-1.74, P = 0.899) in HR > 80 bpm. Univariate Cox regression showed that the unadjusted hazard ratios for mortality were 0.52 (95% CI 0.33-0.84, P = 0.003) in patients with beta-blocker as compared patients without beta-blocker. Multivariate Cox regression showed that the adjusted hazard ratios for mortality were 0.48 (95% CI 0.26-0.87, P = 0.016) in patients with beta-blocker as compared patients without beta-blocker. CONCLUSIONS: HR is independently associated with increased all-cause mortality in SR and a lower HR (≤ 60 bpm) is favorable for better outcome in HFpEFpatients with SR. Beta-blocker use is associated with reduced mortality and a lower HR is associated with reduced mortality in HFpEFpatients with SR.
Authors: Melissa H Kong; Linda K Shaw; Christopher O'Connor; Robert M Califf; Michael A Blazing; Sana M Al-Khatib Journal: Ann Noninvasive Electrocardiol Date: 2010-07 Impact factor: 1.468
Authors: D Roy; M Talajic; P Dorian; S Connolly; M J Eisenberg; M Green; T Kus; J Lambert; M Dubuc; P Gagné; S Nattel; B Thibault Journal: N Engl J Med Date: 2000-03-30 Impact factor: 91.245
Authors: Frederick A Masoudi; Edward P Havranek; Grace Smith; Ronald H Fish; John F Steiner; Diana L Ordin; Harlan M Krumholz Journal: J Am Coll Cardiol Date: 2003-01-15 Impact factor: 24.094
Authors: Shi-Jun Li; Ulrik Sartipy; Lars H Lund; Ulf Dahlström; Martin Adiels; Max Petzold; Michael Fu Journal: Circ Heart Fail Date: 2015-08-04 Impact factor: 8.790
Authors: Bart A Mulder; Dirk J Van Veldhuisen; Harry J G M Crijns; Jan G P Tijssen; Hans L Hillege; Marco Alings; Michiel Rienstra; Hessel F Groenveld; Maarten P Van den Berg; Isabelle C Van Gelder Journal: Eur J Heart Fail Date: 2013-06-12 Impact factor: 15.534
Authors: Michiel Rienstra; Kevin Damman; Bart A Mulder; Isabelle C Van Gelder; John J V McMurray; Dirk J Van Veldhuisen Journal: JACC Heart Fail Date: 2013-02-04 Impact factor: 12.035